The Effect of Taxol on some Blood Parameters and Study of Histopathological Changes in the Kidneys of Laboratory Rats

• Zahraa Y. Hammood

  Department of Biology, College of Education for Pure Science, University of Thi-Qar

• Alaa R. Rashid

  Department of Biology, College of Education for Pure Science, University of Thi-Qar

Taxol is a microtubule inhibitor drug widely used in treatment of many types of cancer. In the present study Taxol at different doses if the rats were randomly divided into three groups, each group containing 12 laboratory rats, as follows: The control group consisted of 12 rats injected with 0.5 ml of distilled water. The low dose group consisted of 12 rats injected with 2 mg/kg of Taxol intraperitoneally. The high dose group consisted of 12 rats injected with 4 mg/kg of Taxol intraperitoneally. The results of histological examination of tissue sections showed pathological histological changes in the kidneys of laboratory rats. The results of the current study showed a significant decrease below the probability level of P≤0.05 in blood parameters including white blood cell count and percentage of lymphocytes, neutrophils, eosinophils and basophils in laboratory rats treated with (TAXOL) at two doses (2.4 mg/kg). The results of the study showed a significant decrease in the number of red blood cells below the probability level of P≤0.05 at both high and low doses, noting that the effect of the high dose was greater than the low dose. The results of histological sections of the kidneys of laboratory rats treated with Taxol showed blood congestion in the blood vessels with degenerations in the proximal and distal endothelial cells and atrophy of the renal glomeruli

 Highlights:

1. Groups: Control, 2 mg/kg Taxol, 4 mg/kg Taxol (n=12/group).
2. Blood: Taxol reduced WBC, RBC, lymphocytes, neutrophils significantly (P≤0.05).
3. Kidney: Congestion, cell degeneration, glomerular atrophy observed in treated rats.

Keywords: Taxol, Chemotherapy, nephrotoxicity, Hematological

[1]. L. Rajman, K. Chwalek, and D. A. Sinclair, “Therapeutic potential of NAD-Boosting molecules: the In vivo Evidence,” Cell Metabolism, vol. 27, no. 3, pp. 529–547, Mar. 2018, doi: 10.1016/j.cmet.2018.02.011.

[2]. A. Gilman, “The initial clinical trial of nitrogen mustard,” The American Journal of Surgery, vol. 105, no. 5, pp. 574–578, May 1963, doi: 10.1016/0002-9610(63)90232-0.

[3]. Q. Q. Li et al., “Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M,” Cellular and Molecular Life Sciences, vol. 75, no. 5, pp. 939–963, Oct. 2017, doi: 10.1007/s00018-017-2681-z.

[4]. S. O. Rabah, “Acute Taxol nephrotoxicity: Histological and ultrastructural studies of mice kidney parenchyma,” Saudi Journal of Biological Sciences, vol. 17, no. 2, pp. 105–114, Feb. 2010, doi: 10.1016/j.sjbs.2010.02.003.

[5]. J. D. Generaal et al., “Hyperbaric oxygen therapy for radiation-induced tissue injury following sarcoma treatment: A retrospective analysis of a Dutch cohort,” PLoS ONE, vol. 15, no. 6, p. e0234419, Jun. 2020, doi: 10.1371/journal.pone.0234419.

[6]. U. Uyeturk, S. H. Arslan, M. K. Yuksel, and F. Altuntas, “Paclitaxel therapy and immune thrombocytopenic purpura: Coincidence or association?,” Turkish Journal of Hematology, vol. 28, no. 2, pp. 151–152, May 2011, doi: 10.5152/tjh.2011.35.

[7]. G. Molyneux et al., “The haemotoxicity of mitomycin in a repeat dose study in the female CD‐1 mouse,” International Journal of Experimental Pathology, vol. 86, no. 6, pp. 415–430, Nov. 2005, doi: 10.1111/j.0959-9673.2005.00452.x.

[8]. V. W. Lee and D. C. Harris, “Adriamycin nephropathy: A model of focal segmental glomerulosclerosis,” Nephrology, vol. 16, no. 1, pp. 30–38, Jul. 2010, doi: 10.1111/j.1440-1797.2010.01383.x.

[9]. G. J. Handelman and N. W. Levin, “Iron and anemia in human biology: a review of mechanisms,” Heart Failure Reviews, vol. 13, no. 4, pp. 393–404, Mar. 2008, doi: 10.1007/s10741-008-9086-x.

[10]. S. J. Slichter and L. A. Harker, “Preparation and storage of platelet concentrates,” Transfusion, vol. 16, no. 1, pp. 8–12, Jan. 1976, doi: 10.1046/j.1537-2995.1976.16176130842.x.

[11]. V. Singh, S. Subramaniam, S. Shyama, M. Jagadeesan, and S. Devi, “Changes in Erythrocyte Membrane Lipids in Breast Cancer after Radiotherapy and Chemotherapy,” Chemotherapy, vol. 42, no. 1, pp. 65–70, Jan. 1996, doi: 10.1159/000239423.

[12]. Z. Tothova et al., “FOXOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress,” Cell, vol. 128, no. 2, pp. 325–339, Jan. 2007, doi: 10.1016/j.cell.2007.01.003.

[13]. B.N.F, British National Formulary a Joint Publication of the British Medical Association and the Royal Pharmaceutical Society of Great British, 2001. https://bnf.nice.org.uk/

[14]. L. Jianhua, M. Xueqin, and H. Jifen, “Expression and clinical significance of LXRα and SREBP-1c in placentas of preeclampsia,” Open Medicine, vol. 11, no. 1, pp. 292–296, Jan. 2016, doi: 10.1515/med-2016-0057.

[15]. S. Siena, S. Secondino, L. Giannetta, O. Carminati, and P. Pedrazzoli, “Optimising management of neutropenia and anaemia in cancer chemotherapy—advances in cytokine therapy,” Critical Reviews in Oncology/Hematology, vol. 48, pp. S39–S47, Oct. 2003, doi: 10.1016/j.critrevonc.2003.05.002.

[16]. B. D. Humphreys, R. J. Soiffer, and C. C. Magee, “Renal Failure Associated with Cancer and Its Treatment,” Journal of the American Society of Nephrology, vol. 16, no. 1, pp. 151–161, Dec. 2004, doi: 10.1681/asn.2004100843.

[17]. A. Merouani, S. A. Davidson, and R. W. Schrier, “Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone,” American Journal of Nephrology, vol. 17, no. 1, pp. 53–58, Jan. 1997, doi: 10.1159/000169072.

[18]. T.-S. Chen, X.-P. Wang, L. Sun, L.-X. Wang, D. Xing, and M. Mok, “Taxol induces caspase-independent cytoplasmic vacuolization and cell death through endoplasmic reticulum (ER) swelling in ASTC-a-1 cells,” Cancer Letters, vol. 270, no. 1, pp. 164–172, Jun. 2008, doi: 10.1016/j.canlet.2008.05.008.

[19]. D. Selimovic, M. Hassan, Y. Haikel, and U. R. Hengge, “Taxol-induced mitochondrial stress in melanoma cells is mediated by activation of c-Jun N-terminal kinase (JNK) and p38 pathways via uncoupling protein 2,” Cellular Signalling, vol. 20, no. 2, pp. 311–322, Nov. 2007, doi: 10.1016/j.cellsig.2007.10.015.

[20]. S. O. Rabah, “Acute Taxol nephrotoxicity: Histological and ultrastructural studies of mice kidney parenchyma,” Saudi Journal of Biological Sciences, vol. 17, no. 2, pp. 105–114, Feb. 2010, doi: 10.1016/j.sjbs.2010.02.003.

[21]. T. Oshima et al., “Role of nitric oxide in human gastric cancer cells treated with 5-fluorouracil,” Oncology Reports, Jul. 2001, doi: 10.3892/or.8.4.847.

[22]. D. B. Longley, D. P. Harkin, and P. G. Johnston, “5-Fluorouracil: mechanisms of action and clinical strategies,” Nature Reviews. Cancer, vol. 3, no. 5, pp. 330–338, May 2003, doi: 10.1038/nrc1074.

[23]. S.-J. Park, C.-H. Wu, J. D. Gordon, X. Zhong, A. Emami, and A. R. Safa, “Taxol induces caspase-10-dependent apoptosis,” Journal of Biological Chemistry, vol. 279, no. 49, pp. 51057–51067, Sep. 2004, doi: 10.1074/jbc.m406543200.

[24]. S. Ayla et al., “Doxorubicin induced nephrotoxicity: Protective effect of nicotinamide,” International Journal of Cell Biology, vol. 2011, pp. 1–9, Jan. 2011, doi: 10.1155/2011/390238.